查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
细胞解离市场规模，占有率及趋势分析:各产品，各组织，各类型，各终端用户，各地区展望，竞争策略，至2030年的各市场区隔预测
市场调查报告书
商品编码
1089964

细胞解离市场规模，占有率及趋势分析:各产品，各组织，各类型，各终端用户，各地区展望，竞争策略，至2030年的各市场区隔预测

Cell Dissociation Market Size, Share & Trends Analysis By Product, By Tissue, By Type, By End-User, Regional Outlook, Competitive Strategies and Segment Forecasts to 2030
出版日期: | 出版商: SPER Market Research Pvt. Ltd. | 英文 208 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

全球细胞解离的市场规模，预计今后以13.5％的年复合成长率扩大，至2030年达到8亿8,148万美元。细胞为基础的研究变得繁盛，製药公司和生物科技企业数量增加，成为市场扩大的要素。

本报告提供全球细胞解离市场相关调查，市场概要，以及各产品，各组织，各类型，各终端用户，各地区的趋势，及加入此市场的主要企业的简介等资讯。

目录

第1章 简介

第2章 调查手法

第3章 摘要整理

第4章 市场动态

  • 成长要素，阻碍因素，机会，课题的分析
    • 促进因素
    • 阻碍因素
    • 市场机会
    • 课题
  • COVID-19细胞解离市场的影响

第5章 市场变数及预测

  • SWOT分析
  • PESTEL分析
  • 波特的五力分析
  • 热图分析

第6章 全球细胞解离市场，各产品，2019年～2030年(100万美元)

  • 酵素的解离生成物
    • 胶原酵素
    • DNase
    • 弹性蛋白酶
    • 玻糖醛酸酶
    • 木瓜蛋白酶
    • 胰蛋白酶
  • 酵素的解离生成物
  • 设备

第7章 全球细胞解离市场，各组织，2019年～2030年(100万美元)

  • 结缔组织
  • 表皮组织
  • 其他(骨骼及肌肉组织)

第8章 全球细胞解离市场，各类型，2019年～2030年(100万美元)

  • 细胞的剥离
  • 组织的解离

第9章 全球细胞解离市场，各终端用户，2019年～2030年(100万美元)

  • 製药公司、生物科技企业
  • 学术研究机关
  • 其他

第10章 全球细胞解离市场，各地区，2019年～2030年(100万美元)

  • 北美
  • 欧洲
  • 亚太地区
  • 南美
  • 中东、非洲

第11章 企业简介

  • Abeomics
  • AcceGen
  • Alstem
  • Becton
  • Biological Industries
  • Capricorn Scientific
  • Central Drug House
  • Cytiva
  • Dickinson and Company
  • Gemini Bio
  • Genlantis
  • Innovative Cell Technologies
  • Miltenyi Biotec
  • Neuromics
  • PromoCell GmbH
  • Roche Diagnostics
  • STEMCELL Technologies
  • Thermo Fisher Scientific
  • VitaCyte
  • Worthington Biochemical Corporation
简介目录
Product Code: BIOT2230

Global Cell Dissociation Market projected to be worth USD 881.48 million by 2030.

According to SPER Market Research, the Cell Dissociation Market estimated to reach USD 881.48 million by 2030 with a CAGR of 13.5%. Growing occurrence of cell-based research, the growing figure of pharmaceutical and biotechnology companies; these are the fuel to the expansion of the market.

Impact of COVID-19 on the Cell Dissociation Market

The outbreak of COVID-19 has a positive impact on the growth of the market.

Scope of the report:

  • Market size available for years: 2019-2030
  • Base year considered: 2021
  • Forecast period: 2022-2030
  • Segments covered: By Product, By Tissue, By type, By End-User, By Region
  • Geographies covered: North America, Europe, Asia Pacific, Latin America, Middle East, Africa
  • Companies Covered: Abeomics, AcceGen, Alstem, Becton, Biological Industries, Capricorn Scientific, Central Drug House, Cytiva, Dickinson and Company, Gemini Bio, Genlantis, Innovative Cell Technologies, Miltenyi Biotec, Neuromics, PromoCell GmbH, Roche Diagnostics, STEMCELL Technologies, Thermo Fisher Scientific, VitaCyte, Worthington Biochemical Corporation

Driver:

Increasing research & development activities in biopharmaceutical companies, encouraging funding scenario for cancer research, growing occurrence and incidence of chronic and infectious diseases, growing focus on personalized medicine, growing government funding for cell-based research; are the key drivers for the market expansion.

Restraint:

Costly cell-based researches, short of of infrastructure for cell-based research in emerging economies, can restraint the expansion of the market.

Opportunity:

Growth opportunities in emerging markets, development in stem cell research, appearance of advanced tissue dissociation enzyme products, recognition of enzyme-free dissociation products over enzymatic dissociation products.

Challenges:

Survival of small players and new entrants, ethical concerns regarding research in cell biology, are the challenges of the market.

Global Cell Dissociation Market, By Product:

Based on the Product, Global Cell Dissociation Market is segmented as; Enzymatic Dissociation Products (Collagenase, DNase, Elastase, Hyaluronidase, Papain, Trypsin), Enzymatic Dissociation Products, Instruments.

Global Cell Dissociation Market, By Tissue:

Based on the Tissue, Global Cell Dissociation Market is segmented as; Connective Tissues, Epithelial Tissues, Other type tissues (skeletal and muscles tissues).

Global Cell Dissociation Market, By Type:

Based on the Type, Global Cell Dissociation Market is segmented as; Cell detachment, Tissue dissociation.

Global Cell Dissociation Market, By End-User:

Based on the End-User, Global Cell Dissociation Market is segmented as; Pharmaceutical and Biotechnology companies, Research and Academics, other end users.

Global Cell Dissociation Market, By Region:

North America owns the biggest share of the market; this is due to the concentration of giant companies and growing research in Pharma and biopharma companies.

Table of Contents

1. Introduction

  • 1.1. Scope of the report
  • 1.2. Market segment analysis

2. Research Methodology

  • 2.1 Research data source
    • 2.1.1 Secondary data
    • 2.1.2 Primary data
    • 2.1.3 SPER's internal database
    • 2.1.4 Premium insight from KOL's
  • 2.2 Market size estimation
    • 2.2.1 Top-down and Bottom-up approach
  • 2.3 Data triangulation

3. Executive Summary

4. Market Dynamics

  • 4.1. Driver, Restraint, Opportunity and Challenges analysis
    • 4.1.1 Drivers
    • 4.1.2 Restraints
    • 4.1.3 Opportunities
    • 4.1.4 Challenges
  • 4.2. COVID-19 Impacts of the Cell Dissociation Market

5. Market variables and outlook

  • 5.1. SWOT analysis
    • 5.1.1 Strengths
    • 5.1.2 Weaknesses
    • 5.1.3 Opportunities
    • 5.1.4 Threats
  • 5.2. PESTEL analysis
    • 5.2.1 Political landscape
    • 5.2.2 Economic landscape
    • 5.2.3 Social landscape
    • 5.2.4 Technological landscape
    • 5.2.5 Environmental landscape
    • 5.2.6 Legal landscape
  • 5.3. PORTER'S five forces analysis
    • 5.3.1 Bargaining power of suppliers
    • 5.3.2 Bargaining power of Buyers
    • 5.3.3 Threat of Substitute
    • 5.3.4 Threat of new entrant
    • 5.3.5 Competitive rivalry
  • 5.4. Heat map analysis

6. Global Cell Dissociation Market, By Product, 2019-2030 (USD Million)

  • 6.1. Enzymatic Dissociation Products
    • 6.1.1. Collagenase
    • 6.1.2. DNase
    • 6.1.3. Elastase
    • 6.1.4. Hyaluronidase
    • 6.1.5. Papain
    • 6.1.6. Trypsin
  • 6.2. Enzymatic Dissociation Products
  • 6.3. Instruments

7. Global Cell Dissociation Market, By Tissue, 2019-2030 (USD Million)

  • 7.1. Connective Tissues
  • 7.2. Epithelial Tissues
  • 7.3. Other type tissues (skeletal and muscles tissues)

8. Global Cell Dissociation Market, By Type, 2019-2030 (USD Million)

  • 8.1. Cell detachment
  • 8.2. Tissue dissociation

9. Global Cell Dissociation Market, By End-User, 2019-2030 (USD Million)

  • 9.1. Pharmaceutical and Biotechnology companies
  • 9.2. Research and Academics
  • 9.3. other end users

10. Global Cell Dissociation Market, By Region, 2019-2030 (USD Million)

  • 10.1. North America
    • 10.1.1. United States
    • 10.1.2. Canada
    • 10.1.3. Mexico
  • 10.2. Europe
    • 10.2.1. Germany
    • 10.2.2. United Kingdom
    • 10.2.3. France
    • 10.2.4. Italy
    • 10.2.5. Spain
    • 10.2.6. Rest of Europe
  • 10.3. Asia-Pacific
    • 10.3.1. China
    • 10.3.2. Japan
    • 10.3.3. India
    • 10.3.4. Australia
    • 10.3.5. South Korea
    • 10.3.6. Rest of Asia-Pacific
  • 10.4. South America
    • 10.4.1. Brazil
    • 10.4.2. Argentina
    • 10.4.3. Rest of South America
  • 10.5. Middle East & Africa
    • 10.5.1. Kingdom of Saudi Arabia
    • 10.5.2. United Arab Emirates
    • 10.5.3. Rest of Middle East & Africa

11. Company Profiles

  • 11.1. Abeomics
    • 11.1.1. Company details
    • 11.1.2. Financial outlook
    • 11.1.3. Product summary
    • 11.1.4. Recent developments
  • 11.2. AcceGen
    • 11.2.1. Company details
    • 11.2.2. Financial outlook
    • 11.2.3. Product summary
    • 11.2.4. Recent developments
  • 11.3. Alstem
    • 11.3.1. Company details
    • 11.3.2. Financial outlook
    • 11.3.3. Product summary
    • 11.3.4. Recent developments
  • 11.4. Becton
    • 11.4.1. Company details
    • 11.4.2. Financial outlook
    • 11.4.3. Product summary
    • 11.4.4. Recent developments
  • 11.5. Biological Industries
    • 11.5.1. Company details
    • 11.5.2. Financial outlook
    • 11.5.3. Product summary
    • 11.5.4. Recent developments
  • 11.6. Capricorn Scientific
    • 11.6.1. Company details
    • 11.6.2. Financial outlook
    • 11.6.3. Product summary
    • 11.6.4. Recent developments
  • 11.7. Central Drug House
    • 11.7.1. Company details
    • 11.7.2. Financial outlook
    • 11.7.3. Product summary
    • 11.7.4. Recent developments
  • 11.8. Cytiva
    • 11.8.1. Company details
    • 11.8.2. Financial outlook
    • 11.8.3. Product summary
    • 11.8.4. Recent developments
  • 11.9. Dickinson and Company

Company details

Financial outlook

Product summary

Recent developments

  • 11.10. Gemini Bio
    • 11.10.1. Company details
    • 11.10.2. Financial outlook
    • 11.10.3. Product summary
    • 11.10.4. Recent developments
  • 11.11. Genlantis
    • 11.11.1. Company details
    • 11.11.2. Financial outlook
    • 11.11.3. Product summary
    • 11.11.4. Recent developments
  • 11.12. Innovative Cell Technologies
    • 11.12.1. Company details
    • 11.12.2. Financial outlook
    • 11.12.3. Product summary
    • 11.12.4. Recent developments
  • 11.13. Miltenyi Biotec
    • 11.13.1. Company details
    • 11.13.2. Financial outlook
    • 11.13.3. Product summary
    • 11.13.4. Recent developments
  • 11.14. Neuromics
    • 11.14.1. Company details
    • 11.14.2. Financial outlook
    • 11.14.3. Product summary
    • 11.14.4. Recent developments
  • 11.15. PromoCell GmbH
    • 11.15.1. Company details
    • 11.15.2. Financial outlook
    • 11.15.3. Product summary
    • 11.15.4. Recent developments
  • 11.16. Roche Diagnostics
    • 11.16.1. Company details
    • 11.16.2. Financial outlook
    • 11.16.3. Product summary
    • 11.16.4. Recent developments
  • 11.17. STEMCELL Technologies
    • 11.17.1 Company details
    • 11.17.2 Financial outlook
    • 11.17.3 Product summary
    • 11.17.4 Recent developments
  • 11.18. Thermo Fisher Scientific
    • 11.18.1. Company details
    • 11.18.2. Financial outlook
    • 11.18.3. Product summary
    • 11.18.4. Recent developments
  • 11.19. VitaCyte
    • 11.19.1. Company details
    • 11.19.2. Financial outlook
    • 11.19.3. Product summary
    • 11.19.4. Recent developments
  • 11.20. Worthington Biochemical Corporation
    • 11.20.1. Company details
    • 11.20.2. Financial outlook
    • 11.20.3. Product summary
    • 11.20.4. Recent developments

10. Global Cell Dissociation Market, By Region, 2019-2030 (USD Million)

  • 10.1. North America
    • 10.1.1. United States
    • 10.1.2. Canada
    • 10.1.3. Mexico
  • 10.2. Europe
    • 10.2.1. Germany
    • 10.2.2. United Kingdom
    • 10.2.3. France
    • 10.2.4. Italy
    • 10.2.5. Spain
    • 10.2.6. Rest of Europe
  • 10.3. Asia-Pacific
    • 10.3.1. China
    • 10.3.2. Japan
    • 10.3.3. India
    • 10.3.4. Australia
    • 10.3.5. South Korea
    • 10.3.6. Rest of Asia-Pacific
  • 10.4. South America
    • 10.4.1. Brazil
    • 10.4.2. Argentina
    • 10.4.3. Rest of South America
  • 10.5. Middle East & Africa
    • 10.5.1. Kingdom of Saudi Arabia
    • 10.5.2. United Arab Emirates
    • 10.5.3. Rest of Middle East & Africa

11. Company Profiles

  • 11.1. Abeomics
    • 11.1.1. Company details
    • 11.1.2. Financial outlook
    • 11.1.3. Product summary
    • 11.1.4. Recent developments
  • 11.2. AcceGen
    • 11.2.1. Company details
    • 11.2.2. Financial outlook
    • 11.2.3. Product summary
    • 11.2.4. Recent developments
  • 11.3. Alstem
    • 11.3.1. Company details
    • 11.3.2. Financial outlook
    • 11.3.3. Product summary
    • 11.3.4. Recent developments
  • 11.4. Becton
    • 11.4.1. Company details
    • 11.4.2. Financial outlook
    • 11.4.3. Product summary
    • 11.4.4. Recent developments
  • 11.5. Biological Industries
    • 11.5.1. Company details
    • 11.5.2. Financial outlook
    • 11.5.3. Product summary
    • 11.5.4. Recent developments
  • 11.6. Capricorn Scientific
    • 11.6.1. Company details
    • 11.6.2. Financial outlook
    • 11.6.3. Product summary
    • 11.6.4. Recent developments
  • 11.7. Central Drug House
    • 11.7.1. Company details
    • 11.7.2. Financial outlook
    • 11.7.3. Product summary
    • 11.7.4. Recent developments
  • 11.8. Cytiva
    • 11.8.1. Company details
    • 11.8.2. Financial outlook
    • 11.8.3. Product summary
    • 11.8.4. Recent developments
  • 11.9. Dickinson and Company

Company details

Financial outlook

Product summary

Recent developments

  • 11.10. Gemini Bio
    • 11.10.1. Company details
    • 11.10.2. Financial outlook
    • 11.10.3. Product summary
    • 11.10.4. Recent developments
  • 11.11. Genlantis
    • 11.11.1. Company details
    • 11.11.2. Financial outlook
    • 11.11.3. Product summary
    • 11.11.4. Recent developments
  • 11.12. Innovative Cell Technologies
    • 11.12.1. Company details
    • 11.12.2. Financial outlook
    • 11.12.3. Product summary
    • 11.12.4. Recent developments
  • 11.13. Miltenyi Biotec
    • 11.13.1. Company details
    • 11.13.2. Financial outlook
    • 11.13.3. Product summary
    • 11.13.4. Recent developments
  • 11.14. Neuromics
    • 11.14.1. Company details
    • 11.14.2. Financial outlook
    • 11.14.3. Product summary
    • 11.14.4. Recent developments
  • 11.15. PromoCell GmbH
    • 11.15.1. Company details
    • 11.15.2. Financial outlook
    • 11.15.3. Product summary
    • 11.15.4. Recent developments
  • 11.16. Roche Diagnostics
    • 11.16.1. Company details
    • 11.16.2. Financial outlook
    • 11.16.3. Product summary
    • 11.16.4. Recent developments
  • 11.17. STEMCELL Technologies
    • 11.17.1 Company details
    • 11.17.2 Financial outlook
    • 11.17.3 Product summary
    • 11.17.4 Recent developments
  • 11.18. Thermo Fisher Scientific
    • 11.18.1. Company details
    • 11.18.2. Financial outlook
    • 11.18.3. Product summary
    • 11.18.4. Recent developments
  • 11.19. VitaCyte
    • 11.19.1. Company details
    • 11.19.2. Financial outlook
    • 11.19.3. Product summary
    • 11.19.4. Recent developments
  • 11.20. Worthington Biochemical Corporation
    • 11.20.1. Company details
    • 11.20.2. Financial outlook
    • 11.20.3. Product summary
    • 11.20.4. Recent developments